"Goserelin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.
| Descriptor ID |
D017273
|
| MeSH Number(s) |
D06.472.699.327.740.320.340 D12.644.400.400.740.320.340 D12.644.456.460.315 D12.644.548.365.740.320.340 D12.776.631.650.405.740.320.340
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Goserelin".
Below are MeSH descriptors whose meaning is more specific than "Goserelin".
This graph shows the total number of publications written about "Goserelin" by people in this website by year, and whether "Goserelin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Goserelin" by people in Profiles.
-
Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 11; 19(11):1504-1515.